公开(公告)号：EP3353196A1

公开(公告)日：2018-08-01

申请号：EP16775121.3

申请日：2016-09-21

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Fondation Imagine ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Université Paris Descartes ,  Centre National de la Recherche Scientifique (CNRS) ,  Université de Bourgogne ,  CNAM-CONSERVATOIRE NATIONAL DES ARTS ET METIERS

发明人： BELAID-CHOUCAIR, Zakia ,  HERMINE, Olivier ,  MONTES, Matthieu ,  GARRIDO-FLEURY, Carmen ,  SEIGNEURIC, Renaud ,  MARCION, Guillaume

IPC分类号： C07K14/575 ,  C07K14/72 ,  C07K14/705

CPC分类号： C07K14/475 ,  A61K38/1866 ,  A61K39/3955 ,  A61K2039/505 ,  A61P35/00 ,  C07K14/5759 ,  C07K14/705 ,  C07K14/72 ,  C07K16/22 ,  C07K2317/76

摘要： The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.

公开(公告)号：EP3906415A1

公开(公告)日：2021-11-10

申请号：EP20700002.7

申请日：2020-01-02

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Fondation Imagine ,  Université Paris Descartes ,  Centre National de la Recherche Scientifique (CNRS) ,  Université Paris-Saclay

发明人： HERMINE, Olivier ,  ROSSIGNOL, Julien ,  BELAID-CHOUCAIR, Zakia ,  FOUQUET, Guillemette ,  COURONNE, Lucile ,  DUSSIOT, Michael ,  RIGNAULT-BRICARD, Rachel ,  COMAN, Tereza ,  GUILLEM, Flavia ,  LEPELLETIER, Yves ,  RENAND, Amédée ,  MILPIED, Pierre

IPC分类号： G01N33/574

公开(公告)号：EP3108255B1

公开(公告)日：2020-08-12

申请号：EP15704806.7

申请日：2015-02-18

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Paris Descartes ,  Fondation Imagine ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Centre National de la Recherche Scientifique (C.N.R.S.) ,  Université Grenoble Alpes ,  Commissariat à l'Energie Atomique et aux Energies Alternatives ,  Université de Bourgogne

发明人： BELAID-CHOUCAIR, Zakia ,  HERMINE, Olivier ,  GARRIDO-FLEURY, Carmen ,  COCHET, Claude ,  FILHOL-COCHET, Odile ,  SEIGNEURIC, Renaud

IPC分类号： G01N33/574 ,  G01N33/50

公开(公告)号：EP3108255A1

公开(公告)日：2016-12-28

申请号：EP15704806.7

申请日：2015-02-18

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Paris Descartes ,  Fondation Imagine ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Centre National de la Recherche Scientifique (C.N.R.S.) ,  Université Grenoble Alpes ,  Commissariat à l'Energie Atomique et aux Energies Alternatives ,  Université de Bourgogne

发明人： BELAID-CHOUCAIR, Zakia ,  HERMINE, Olivier ,  GARRIDO-FLEURY, Carmen ,  COCHET, Claude ,  FILHOL-COCHET, Odile ,  SEIGNEURIC, Renaud

IPC分类号： G01N33/574 ,  G01N33/50

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

摘要翻译： 本发明涉及用于治疗疾病由NRP-1 / OBR复杂信号传导途径介导的疾病的方法和药物组合物。 特别地，本发明涉及一种用于治疗选自下组在有需要的受试者的癌症，肥胖症和肥胖症相关疾病，厌食，自身免疫性疾病和感染性疾病由......组成，其包括施用与治疗有效量的本发明的疾病 的NRP-1 / OBR信号传导途径的拮抗剂。

公开(公告)号：EP4059569A1

公开(公告)日：2022-09-21

申请号：EP22157031.0

申请日：2020-01-02

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  Assistance Publique-Hôpitaux de Paris ,  Fondation Imagine ,  Centre national de la recherche scientifique ,  Université de Paris ,  Université Paris-Saclay

发明人： HERMINE, Olivier ,  ROSSIGNOL, Julien ,  BELAID-CHOUCAIR, Zakia ,  FOUQUET, Guillemette ,  COURONNE, Lucile ,  DUSSIOT, Michael ,  RIGNAULT-BRICARD, Rachel ,  COMAN, Tereza ,  GUILLEM, Flavia ,  LEPELLETIER, Yves ,  RENAND, Amédée ,  MILPIED, Pierre

IPC分类号： A61P35/00 ,  C07K16/28 ,  G01N33/574

摘要： Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PDl (e.g. pembrolizumab). Finally, the combination of anti-NRPl and anti-PDl antibodies is synergistic in human, specifically in CD8+ T -cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PDl antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.